FHHP-RCT: Family Heart Health Program: Randomized, Controlled Trial

Sponsor
Ottawa Heart Institute Research Corporation (Other)
Overall Status
Completed
CT.gov ID
NCT00552591
Collaborator
Heart and Stroke Foundation of Canada (Other)
426
1
2
48
8.9

Study Details

Study Description

Brief Summary

Background: Family members (spouses, siblings, offspring) of patients with coronary heart disease (CHD) may themselves be at increased risk for developing CHD for genetic, biochemical and/or behavioural reasons. Targeted approaches aimed at family members of those with established CHD may be a cost-effective way to identify high-risk persons and link them to effective risk factor modification. During pilot testing we found 29% of family members of patients recently hospitalized at our institution had ≥ 3 CHD risk factors. Encouragingly, they indicated high levels of "readiness" to change underlying risk behaviours such as cigarette smoking and physical inactivity. We have developed a 12-week family heart health program featuring a personal plan for achieving risk factor goals and weekly contact with a heart health educator. This intervention needs to be fully tested.

Research Aims:
In this study, we will:
  1. Compare the effects of a targeted family heart health (FHH) screening, counselling and follow-up program versus usual care (UC) for reducing participants total cholesterol/high density lipoprotein (TC/HDL) ratio 52 weeks after program entry, in family members of patients recently hospitalized with CHD;

  2. Compare the effects of the FHH program versus UC on modifiable components comprising the Framingham score, including: smoking status; systolic blood pressure; total cholesterol; and high density lipoprotein cholesterol;

  3. Compare the effects of the FHH program versus UC on: lifestyle-related factors (dietary patterns, leisure time exercise, body composition); medication use (anti-lipemic medications, anti-hypertensive medications, pharmacotherapies for smoking cessation); and use of healthcare resources (physician visits, hospitalization days, number of laboratory and diagnostic tests and procedures).

Condition or Disease Intervention/Treatment Phase
  • Behavioral: 12-week risk reduction program, managed by a Heart Health Educator
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
426 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Family Heart Health Program: Randomized, Controlled Trial
Study Start Date :
Sep 1, 2007
Actual Primary Completion Date :
Sep 1, 2011
Actual Study Completion Date :
Sep 1, 2011

Arms and Interventions

Arm Intervention/Treatment
Experimental: 1

Family Heart Health Program

Behavioral: 12-week risk reduction program, managed by a Heart Health Educator
The educator and participant will negotiate a personal plan for achieving the goals through lifestyle change (i.e. smoking cessation, increased exercise, improved nutrition) and, if necessary, pharmacotherapy coordinated by the participant's personal physician. Educational modules have been developed to address specific lifestyle issues including smoking cessation, healthy eating, exercise, and weight management, and will be provided to participants as required. A summary of the risk factor profile and personal plan will be incorporated into a report for the participant's personal physician as well. Participants will also receive telephone-based motivational counseling sessions for 12 weeks to address specific lifestyle issues.

No Intervention: 2

Usual Care

Outcome Measures

Primary Outcome Measures

  1. TC/HDL ratio [one year]

Secondary Outcome Measures

  1. Secondary outcomes of interest will include the modifiable components comprising the Framingham score (smoking status, systolic BP, total cholesterol, HDL- and LDL-cholesterol) [12 weeks and one year]

  2. Use of risk reducing medications, use of health care resources, smoking status, leisure time exercise, dietary patterns, and body composition [12 weeks and one year]

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Spouse, offspring or sibling of patient hospitalized at UOHI within the past 5 years for:
  1. Acute coronary syndrome (ACS);

  2. Elective percutaneous coronary intervention (PCI); or

  3. Bypass surgery (CABG);

  • Willing to provide informed consent;

  • At least one of the following modifiable risk factors:

  1. Current smoker;

  2. Systolic blood pressure ≥ 140 and or Diastolic BP ≥ 90 and/or currently on medication to treat high blood pressure;

  3. Total cholesterol/HDL-cholesterol ratio ≥ 5.0 and/or on antilipemic medication;

  4. Abdominal obesity (for men, waist circumference > 102 cm; for women, waist circumference > 88cm);

  5. Physical Inactivity [<150 min mod, 5-7 d/week or <100 min vig, 4-7 d/week]

  • Geographically available for assessment, intervention and follow-up.
Exclusion Criteria:
  1. Unable to understand English or French;

  2. History of diabetes mellitus or any atherosclerotic disease;

  3. Fasting glucose ≥ 7.0 mmol/L at screening;

  4. Presence of life threatening illness (e.g., known or suspected cancer or other disease with a life expectancy of less than five years);

  5. Chronic kidney disease and/or undergoing dialysis;

  6. Active liver disease;

  7. Pregnant or planning to become pregnant within the next year;

  8. Cognitive impairment;

  9. Other family member already participating in study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Ottawa Heart Institute Ottawa Ontario Canada K1Y 4W7

Sponsors and Collaborators

  • Ottawa Heart Institute Research Corporation
  • Heart and Stroke Foundation of Canada

Investigators

  • Principal Investigator: Robert D Reid, MBA, PhD, Ottawa Heart Institute Research Corporation
  • Study Chair: Andrew L Pipe, MD, Ottawa Heart Institute Research Corporation
  • Study Chair: Lori J Mosca, MD, PhD, New York Presbyterian Hospital
  • Study Chair: Heidi Mochari, MPH, RD, New York Presbyterian Hospital
  • Study Chair: George Wells, PhD, Ottawa Heart Institute Research Corporation
  • Study Chair: Louise J Beaton, MSc, Ottawa Heart Institute Research Corporation
  • Study Chair: Pat O'Farrell, RN, Ottawa Heart Institute Research Corporation
  • Study Chair: Chris M Blanchard, PhD, Dalhousie University
  • Study Chair: Sophia Papadakis, MHA, Ottawa Heart Institute Research Corporation
  • Study Chair: Monika Slovinec D'Angelo, PhD, Ottawa Heart Institute Research Corporation

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ottawa Heart Institute Research Corporation
ClinicalTrials.gov Identifier:
NCT00552591
Other Study ID Numbers:
  • NA 6142
First Posted:
Nov 2, 2007
Last Update Posted:
Mar 10, 2022
Last Verified:
Feb 1, 2022
Keywords provided by Ottawa Heart Institute Research Corporation
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 10, 2022